{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:01:03Z","timestamp":1787029263363,"version":"build-2736575974"},"reference-count":40,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Atrial fibrillation (AF) is a common arrhythmia in clinical practice, and oral anticoagulation is the cornerstone of stroke prevention in AF. Direct oral anticoagulants (DOAC) significantly reduce the incidence of intracerebral hemorrhage with preserved efficacy for preventing stroke compared to vitamin K antagonists (VKA). However, the pivotal randomized controlled trials (RCTs) of DOAC excluded patients with valvular heart disease, especially mitral stenosis, which remains an exclusion criterion for DOAC use. The INVICTUS study was a large multicenter global RCT aimed at evaluating the role of DOAC compared to VKA in stroke prevention among patients with rheumatic valvular AF. In this study, rivaroxaban failed to prove superiority over VKA in preventing the composite primary efficacy endpoints of stroke, systemic embolism, myocardial infarction, and death. Unfortunately, the bleeding rates were not lower with rivaroxaban either. The death and drug discontinuation rates were higher in the DOAC arm. Close to the heels of the dismal results of INVICTUS, an apixaban trial in prosthetic heart valves, PROACT-Xa, was also prematurely terminated due to futility. Hence, for AF complicating moderate-to-severe mitral stenosis or prosthetic valve VKA remains the standard of care. However, DOAC can be used in patients with surgical bioprosthetic valve implantation, TAVR, and other native valve diseases with AF, except for moderate-to-severe mitral stenosis. Factor XI inhibitors represent a breakthrough in anticoagulation as they aim to dissociate thrombosis from hemostasis, thereby indicating a potential to cut down bleeding further. Multiple agents (monoclonal antibodies\u2014e.g., osocimab, anti-sense oligonucleotides\u2014e.g., fesomersen, and small molecule inhibitors\u2014e.g., milvexian) have garnered positive data from phase II studies, and many have entered the phase III studies in AF\/Venous thromboembolism. Future studies on conventional DOAC and new-generation DOAC will shed further light on whether DOAC can dethrone VKA in valvular heart disease.<\/jats:p>","DOI":"10.3390\/ph17111459","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T06:55:37Z","timestamp":1730357737000},"page":"1459","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["From the INVICTUS Trial to Current Considerations: It\u2019s Not Time to Retire Vitamin K Inhibitors Yet!"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2360-7580","authenticated-orcid":false,"given":"Akshyaya","family":"Pradhan","sequence":"first","affiliation":[{"name":"Department of Cardiology, King George\u2019s Medical University, Lucknow 226003, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4682-0967","authenticated-orcid":false,"given":"Somya","family":"Mahalawat","sequence":"additional","affiliation":[{"name":"Department of Cardiology, King George\u2019s Medical University, Lucknow 226003, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0511-2621","authenticated-orcid":false,"given":"Marco Alfonso","family":"Perrone","sequence":"additional","affiliation":[{"name":"Division of Cardiology and CardioLab, Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Rienstra","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomized trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban for rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"ITC33","DOI":"10.7326\/AITC201703070","article-title":"Atrial fibrillation","volume":"166","author":"Zimetbaum","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guidelines for the diagnosis and management of atrial fibrillation: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2147\/TCRM.S84210","article-title":"New oral anticoagulants: Their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events","volume":"11","author":"Mekaj","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ihj.2018.12.007","article-title":"Current status of rheumatic heart disease in India","volume":"71","author":"Negi","year":"2019","journal-title":"Indian. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1161\/CIRCULATIONAHA.120.050347","article-title":"Overestimation of Stroke Risk in Rheumatic Mitral Stenosis and the Implications for Oral Anticoagulation","volume":"142","author":"Karthikeyan","year":"2020","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e005835","DOI":"10.1161\/JAHA.117.005835","article-title":"Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis","volume":"6","author":"Pan","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","article-title":"Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve","volume":"383","author":"Lopes","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonists for atrial fibrillation after TAVR","volume":"385","author":"Unverdorben","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijcard.2022.03.037","article-title":"RIvaroxaban in mitral stenosis (RISE MS): A pilot randomized clinical trial","volume":"356","author":"Sadeghipour","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.amjcard.2022.03.050","article-title":"Comparison of Dabigatran Versus Warfarin Treatment for Prevention of New Cerebral Lesions in Valvular Atrial Fibrillation","volume":"175","author":"Cho","year":"2022","journal-title":"Am. J. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","article-title":"Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients","volume":"49","author":"Lip","year":"2018","journal-title":"Stroke"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"EVIDoa2300067","DOI":"10.1056\/EVIDoa2300067","article-title":"Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve","volume":"2","author":"Wang","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_16","unstructured":"Banerjee, P.S., Das, M.K., and Roy, D. (2021). Mechanical Prosthetic valve on Oral Anticoagulants\u2014How to improve safety. Cardiology Update Book 2021\u2014Cardiological Society of India, Evangel Publishers."},{"key":"ref_17","first-page":"279","article-title":"Safety of Switching from Vitamin K Antagonist to Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the Frail-AF Randomized Control Trial","volume":"149","author":"Joosten","year":"2023","journal-title":"Circulation"},{"key":"ref_18","unstructured":"(2024, October 16). Efficacy and Safety of Edoxaban in Patients with Atrial Fibrillation and Mitral Stenosis (ERTEMIS), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05540587."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e038194","DOI":"10.1136\/bmjopen-2020-038194","article-title":"Protocol, rationale and design of DAbigatran for Stroke PreVention in Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): A randomised, open-label study","volume":"10","author":"Zhou","year":"2020","journal-title":"BMJ Open"},{"key":"ref_20","unstructured":"(2024, October 16). DIrect Oral Anticoagulation and mechaNical Aortic Valve (DIAMOND), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05687448."},{"key":"ref_21","unstructured":"(2024, October 16). The Nordic Aortic Valve Intervention Trial 4 (NOTION-4), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06449469."},{"key":"ref_22","unstructured":"(2024, October 16). COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients with Atrial Fibrillation (COBRRA-AF), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04642430."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jacc.2022.11.057","article-title":"Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week","volume":"81","author":"Harrington","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehac464","article-title":"Factor XI inhibitors: Cardiovascular perspectives","volume":"44","author":"Prisco","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis","volume":"372","author":"Bethune","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","article-title":"Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients with ESRD","volume":"7","author":"Walsh","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.kint.2024.02.024","article-title":"A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis","volume":"106","author":"Winkelmayer","year":"2024","journal-title":"Kidney Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41591-023-02794-7","article-title":"Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: A randomized phase 2 trial","volume":"30","author":"Weitz","year":"2024","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for Prevention of Venous Thromboembolism","volume":"385","author":"Verhamme","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_32","unstructured":"Kumbhani, D.J. (2024, October 08). A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab Compared with Open-Label Rivaroxaban in Patients with Atrial Fibrillation\u2014AZALEA-TIMI 78. In: American College of Cardiology. [Internet]. Available online: https:\/\/www.acc.org\/Latest-in-Cardiology\/Clinical-Trials\/2023\/11\/10\/22\/46\/azalea-timi-71."},{"key":"ref_33","unstructured":"(2024, October 16). A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-Associated VTE (ASTER), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05171049."},{"key":"ref_34","unstructured":"(2024, October 16). A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal\/Genitourinary Cancer and Associated VTE (MAGNOLIA), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05171075."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The contact activation inhibitor AB023 in heparin-free hemodialysis: Results of a randomized phase 2 clinical trial","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/ATVBAHA.123.319692","article-title":"Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Patients with Cancer Undergoing Central Line Placement: A Phase 2 Clinical Trial","volume":"44","author":"Pfeffer","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): A multicentre, randomised, double-blind, double-dummy, dosefinding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): An international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Piccini, J.P., Patel, M.R., Steffel, J., Ferdinand, K., Van Gelder, I.C., Russo, A.M., Ma, C.-S., Goodman, S.G., Oldgren, J., and Hammett, C. (N. Engl. J. Med., 2024). Asundexian Versus Apixaban in Patients with Atrial Fibrillation, N. Engl. J. Med., Epub ahead of print.","DOI":"10.1056\/NEJMoa2407105"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/11\/1459\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:25:02Z","timestamp":1760113502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/11\/1459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["ph17111459"],"URL":"https:\/\/doi.org\/10.3390\/ph17111459","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}